Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

UNCY Unicycive Therapeutics, Inc.

Closed 07-22 16:00:00 EDT

5.57

-0.12

-2.11%

盘后5.57

+0.000.00%

19:34 EDT

High5.77	Low5.55	Vol595.08K
Open5.60	D1 Closing5.69	Amplitude3.95%
Mkt Cap152.58M	Tradable Cap139.10M	Total Shares27.39M
T/O3.35M	T/O Rate2.38%	Tradable Shares24.97M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"UNCY","market":"US","secType":"STK","nameCN":"Unicycive Therapeutics, Inc.","latestPrice":5.57,"timestamp":1784750400000,"preClose":5.69,"halted":0,"volume":595078,"hourTrading":{"tag":"盘后","latestPrice":5.57,"preClose":5.57,"latestTime":"19:34 EDT","volume":1733,"amount":9647.5405,"timestamp":1784763249042,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.021089630931458717,"floatShares":24973600,"shares":27393027,"eps":-2.108803,"marketStatus":"Closed","change":-0.12,"latestTime":"07-22 16:00:00 EDT","open":5.6,"high":5.77,"low":5.545,"amount":3349319.3413834004,"amplitude":0.039543,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.108803,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1784793600000},"marketStatusCode":5,"adr":0,"listingDate":1623988800000,"exchange":"NASDAQ","adjPreClose":5.69,"preHourTrading":{"tag":"盘前","latestPrice":5.6,"preClose":5.69,"latestTime":"09:29 EDT","volume":4587,"amount":26032.8969615,"timestamp":1784726999999,"change":-0.09,"changeRate":-0.015817,"amplitude":0.065026},"postHourTrading":{"tag":"盘后","latestPrice":5.57,"preClose":5.57,"latestTime":"19:34 EDT","volume":1733,"amount":9647.5405,"timestamp":1784763249042,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":0.601667,"impliedVol":1.2605,"impliedVolPercentile":0.4972},"requestUrl":"/m/hq/s/UNCY/wiki","defaultTab":"wiki","newsList":[{"id":"2649679932","title":"Unicycive Therapeutics Posts Corporate Presentation on Kidney Disease Pipeline, Lead Hyperphosphatemia Drug OLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2649679932","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649679932?lang=en_us&edition=fundamental","pubTime":"2026-07-07 04:04","pubTimestamp":1783368245,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics posts corporate presentation on kidney disease pipeline, lead hyperphosphatemia drug OLCUnicycive highlighted oxylanthanum carbonate (OLC) as its lead program for hyperphosphate","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDL3qMXQK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649494116","title":"Unicycive Therapeutics Gets Complete Response Letter from FDA on Resubmitted Oxylanthanum Carbonate NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2649494116","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649494116?lang=en_us&edition=fundamental","pubTime":"2026-07-06 15:21","pubTimestamp":1783322487,"startTime":"0","endTime":"0","summary":"June 30 (Reuters) - Unicycive Therapeutics Inc::*RECEIVES COMPLETE RESPONSE LETTER FROM FDA REGARDING RESUBMITTED OXYLANTHANUM CARBONATE (OLC) NEW DRUG APPLICATION (NDA)*FDA RAISES NO CONCERNS ON CLIN","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nRSD2dG2yj:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648686082","title":"Unicycive Therapeutics Reports Preliminary Q2 2026 Cash Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2648686082","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648686082?lang=en_us&edition=fundamental","pubTime":"2026-07-02 22:58","pubTimestamp":1783004293,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics ( ($UNCY) ) has shared an announcement. As of June 30, 2026, Unicycive Therapeutics reported an unaudited ending cash balanc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/unicycive-therapeutics-reports-preliminary-q2-2026-cash-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/unicycive-therapeutics-reports-preliminary-q2-2026-cash-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UNCY","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648458715","title":"Unicycive Therapeutics price target lowered to $13 from $18 at Benchmark","url":"https://stock-news.laohu8.com/highlight/detail?id=2648458715","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648458715?lang=en_us&edition=fundamental","pubTime":"2026-07-01 20:50","pubTimestamp":1782910220,"startTime":"0","endTime":"0","summary":"Benchmark lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $13 from $18 and keeps a Speculative Buy rating on the shares after t...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-13-from-18-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-13-from-18-at-benchmark-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648517333","title":"Guggenheim Remains a Buy on Unicycive Therapeutics (UNCY)","url":"https://stock-news.laohu8.com/highlight/detail?id=2648517333","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648517333?lang=en_us&edition=fundamental","pubTime":"2026-07-01 18:55","pubTimestamp":1782903340,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Vamil Divan from Guggenheim maintained a Buy rating on Unicycive Therapeutics, with a price target of $37.00. The c...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-unicycive-therapeutics-uncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/guggenheim-remains-a-buy-on-unicycive-therapeutics-uncy-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","UNCY","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648465566","title":"Top Midday Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2648465566","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648465566?lang=en_us&edition=fundamental","pubTime":"2026-07-01 02:41","pubTimestamp":1782844914,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics  said Tuesday it has received a Complete Response Letter from the US Food and Drug Administration over its resubmitted new drug application for oxylanthanum carbonate for treating hyperphosphatemia in patients with chronic kidney disease on dialysis.The letter relates to deficiencies previously identified at third-party manufacturing vendor, the firm said, adding that the FDA inspection of third-party facility did not occur during the resubmission review.Shares sank 37% amid a surge in intraday trading volume to over 17.2 million from a daily average of about 907,000 shares.JPMorgan Chase , which is running a stock and note offering from Sable Offshore , has seen limited investor demand for a loan paying 15%, Bloomberg reported Tuesday, citing people familiar with the matter.Sable shares sank 46% as intraday trading volume catapulted to  over 45.0 million from a daily average of about 3.8 million.Pacira Biosciences  has agreed to sell its Iovera cold-therapy pain","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1894683348.USD","BK4588","JPX","LU0787776722.HKD","LU1116320737.USD","LU0868494708.USD","LU0106831901.USD","BK4585","LU1551013425.SGD","LU1629891620.HKD","IE00BN8TJ469.HKD","LU2756315664.SGD","LU2746668461.USD","IE00BJLML261.HKD","ZBH","LU2237443549.SGD","LU2237443382.USD","IE00BJTD4V19.USD","BK7061","LU1670628061.USD","SOC","LU0496365809.HKD","JPMO","IE00BKVL7J92.USD","LU0187121727.USD","LU0820562030.AUD","LU1145028129.USD","SG9999002224.SGD","LU0234570918.USD","LU0251132253.USD","LU2237443465.HKD","LU0234572021.USD","LU1162221912.USD","LU1267930490.SGD","SOC.AU","LU0820561818.USD","LU2430703095.HKD","PCRX","LU0070302665.USD","LU1720051108.HKD","IE0034235303.USD","JPO","LU0106261372.USD","UNCY","IE00BDCRKT87.USD","LU0215105999.USD","IE00BDRTCR15.USD","LU2236285917.USD","LU0265550946.USD","LU0128525929.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648630585","title":"Unicycive Therapeutics is Maintained at Buy by B. Riley Securities","url":"https://stock-news.laohu8.com/highlight/detail?id=2648630585","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648630585?lang=en_us&edition=fundamental","pubTime":"2026-07-01 01:12","pubTimestamp":1782839520,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/UNCY/analyst-ratings(END) Dow Jones NewswiresJune 30, 2026 13:12 ET","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648563679","title":"Unicycive Therapeutics price target lowered to $15 from $22 at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2648563679","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648563679?lang=en_us&edition=fundamental","pubTime":"2026-07-01 00:35","pubTimestamp":1782837310,"startTime":"0","endTime":"0","summary":"H.C. Wainwright analyst Swayampakula Ramakanth lowered the firm’s price target on Unicycive Therapeutics (UNCY) to $15 from $22 and keeps a Buy rat...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-15-from-22-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-price-target-lowered-to-15-from-22-at-h-c-wainwright-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647571795","title":"Unicycive Therapeutics CRL tied to same vendor deficiency, says B. Riley","url":"https://stock-news.laohu8.com/highlight/detail?id=2647571795","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647571795?lang=en_us&edition=fundamental","pubTime":"2026-06-30 22:50","pubTimestamp":1782831020,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY) announced it received a second FDA Complete Response Letter for its OLC NDA, again tied to third-party manufacturing ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-crl-tied-to-same-vendor-deficiency-says-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-crl-tied-to-same-vendor-deficiency-says-b-riley-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0029874061.USD","LU0128526141.USD","BK4530","BK4588","LU0390134368.USD","IE00BFMHRM44.USD","BK4539","BK4585","UNCY","LU1815336091.USD","BK4139","CRL","LU0757428866.USD","LABU","BK4121"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647553678","title":"Unicycive Shares Plunge After FDA Again Rejects Oxylanthanum Carbonate","url":"https://stock-news.laohu8.com/highlight/detail?id=2647553678","media":"Dow Jones","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647553678?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:55","pubTimestamp":1782820500,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics shares plummeted in premarket trading Tuesday after the U.S. Food and Drug Administration once again turned away the clinical-stage biotechnology company's proposed oxylanthanum","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK4139","BK4585","UNCY","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647755810","title":"Top Premarket Decliners","url":"https://stock-news.laohu8.com/highlight/detail?id=2647755810","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647755810?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:35","pubTimestamp":1782819325,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics  shares were down 37% in Tuesday premarket activity, following the previous session's 8% gain.GMEX Robotics  stock was down 34% after the company said it would implement a 1-for-9 share consolidation of its Class A and Class B ordinary shares.Universe Pharmaceuticals  shares were down 29% after the previous session's 311% rally.Nuvectis Pharma  stock was down 24% after the company priced a secondary offering of 5 million common shares at $20 per share.Decoy Therapeutics  shares were down 21%, following the earlier session's 74% gain.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","UNCY","DCOY","BK4139","UPC","BK4200","NVCT","BK4539","GMEX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647155818","title":"U.S. Stocks on the Move-aerovironment, Oklo","url":"https://stock-news.laohu8.com/highlight/detail?id=2647155818","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647155818?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:33","pubTimestamp":1782819224,"startTime":"0","endTime":"0","summary":"BUZZ-U.S. STOCKS ON THE MOVE-AeroVironment, OkloWorkspace search string for individual stock moves:STXBZThe Day Ahead newsletter: https://refini.tv/3LI4BU7The Morning News Call newsletter: https://ref","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nL6N4320P4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2237443895.HKD","LU1804176565.USD","LU0251142724.SGD","IE00BN8TJ469.HKD","LU0149725797.USD","LU1280957306.USD","LU0320765489.SGD","LU2237443622.USD","LU1791807156.HKD","IE00BZ1G4Q59.USD","LU2264538146.SGD","LU0289961442.SGD","SG9999003800.SGD","IE00BLSP4452.SGD","LU0456855351.SGD","LU0868494708.USD","LU2596442595.SGD","LU0545039389.USD","LU1551013425.SGD","LU0306807586.USD","LU1506573853.SGD","LU2133065610.SGD","BK4207","LU0098860793.USD","SG9999001440.SGD","LU0225283273.USD","LU0069063385.USD","LU0314104364.USD","LU0256863902.USD","LU0965509283.SGD","LU0238689110.USD","LU0310800379.SGD","BK4139","LU0912757837.SGD","LU2125154935.USD","LU0211328371.USD","IE00BKVL7J92.USD","LU1291159041.SGD","MAMA","LU1037948541.HKD","BK4148","LU1244550221.USD","IE0034235188.USD","LU1003077747.HKD","LU0980610538.SGD","LU1883839398.USD","LU1983299246.USD","LU0661504455.SGD","IE00BGHQF631.EUR","LU2237443549.SGD","LU0787776722.HKD","LU1923622614.USD","LU2750360997.AUD","LU1162221912.USD","LU1868836757.USD","LU1066051498.USD","LU0130103400.USD","LU1066053197.SGD","LU2433249047.HKD","GS","SG9999015341.SGD","LU2471134952.CNY","LU2271345857.HKD","IE00BLSP4239.USD","LU2461242641.AUD","IE00BVYPNV92.GBP","IE000BZT7R73.USD","IE00B19Z3B42.SGD","LU1066051225.USD","LU1718418525.SGD","IE00B64PRP62.GBP","LU0052756011.USD","LU0345770308.USD","LU1720051108.HKD","LU0757428866.USD","LU2089284900.SGD","LU2087621335.USD","LU0130102774.USD","LU2361044865.SGD","LU1868836591.USD","LU0128525929.USD","LU1551013342.USD","LU2125154778.USD","LU0265550946.USD","LU0708994859.HKD","BK4007","LU1941712264.USD","LU2129689514.USD","LU0390134368.USD","BK4504","LU0648000940.SGD","AVXX","SG9999014575.USD","LU0130518102.USD","LU1074936037.SGD","LU0106261372.USD","LU2471134523.USD","BK4581","IE000F7OJYX1.SGD","LU0640476718.USD","LU0321505868.SGD","LU0289739343.SGD","LU0477156797.USD","LU1064131342.USD","SG9999001176.USD","BK4533","LU0234570918.USD","LU0203345920.USD","LU0689626769.HKD","IE00BBT3K403.USD","LU0128525689.USD","LU0210528500.USD","LU1035773651.USD","LU0096364046.USD","LU0124676726.USD","IE0002270589.USD","LU0234572021.USD","SGXZ57979304.SGD","LU1061106388.HKD","BK4212","LU2112291526.USD","IE00B3PB1722.GBP","LU1430594728.SGD","LU2357305700.SGD","LU1868836914.USD","LU0267386448.USD","IE0004091025.USD","LU1670627923.USD","LU0985320562.USD","LU1917777945.USD","LU2237438978.USD","IE000WAW04H5.SGD","LU0477156953.USD","LU2237443978.SGD","LU1670628061.USD","BK4559","LU1815336091.USD","SG9999002224.SGD","LU1732800096.USD","LU0265550359.USD","LU1548497426.USD","LU0823416689.USD","LU1201861249.SGD","IE00B3QW5Z07.USD","IE0002141913.USD","LU2491049909.HKD","LU2357627491.SGD","BK4534","LU0306806265.USD","LU1267930227.SGD","LU1069347547.HKD","LU1496350502.SGD","LU1839511570.USD","IE00B2B36J28.USD","VSH","LU0683600562.USD","IE00BVYPNW00.USD","LU2129689605.HKD","LU0553294199.USD","LU2237443465.HKD","SG9999013999.USD","LU1267930573.SGD","LU1571399168.USD","IE00BFTCPJ56.SGD","LU0689472784.USD","LU1023059063.AUD","LU0882574055.USD","LU1868837300.USD","LU2023250504.SGD","AVAV","LU2089283258.USD","ABBV","BK4606","IE00BJT1NW94.SGD","LU1974910355.USD","BK4588","IE00B4R5TH58.HKD","LU0057025933.USD","LU1093756325.SGD","LU0472753341.HKD","LU1720051017.SGD","IE0009355771.USD","LU2750360641.GBP","LU0432979614.USD","LU0511384066.AUD","LU1880398471.USD","LU1929549753.HKD","LU2028103732.USD","LU0942090050.USD","LU0211331839.USD","LU0029864427.USD","IE00BFXG1179.USD","LU0266013472.USD","IE00BSNM7G36.USD","LU0528227936.USD","LU2237443382.USD","LU1585245621.USD","SG9999015952.SGD","IE0004086264.USD","LU2471134796.USD","SG9999011175.SGD","LU1366192091.USD","BK4081","LU1116320901.HKD","LU0122379950.USD","LU1267930490.SGD","LU0053666078.USD","UNCY","OKLO","SG9999001176.SGD","LU0949170772.SGD","BK4552","LU0965509101.SGD","IE00B19Z3581.USD","LU0882574139.USD","GSX","IE00BDGV0183.EUR","LU0130517989.USD","LU0114720955.EUR","LU0256863811.USD","LU0742534661.SGD","LU1934455277.USD","LU0058720904.USD","LU1941712348.USD","MS","LU0106831901.USD","IE000SO60NU8.SGD","BAC","LU0345770993.USD","LU0211327993.USD","BK4585","LU0965508806.USD","LU2125909247.SGD","LU2471134879.HKD","LU0965509010.AUD","LU2265009873.SGD","IE0001KFT4U8.USD","LU2347655156.SGD","IE0000B7K699.USD","LU0861579265.USD","IE00B42XCP33.USD","LU0208291251.USD","BK4516","LU1989772840.SGD","LU2129689431.USD","IE00B7SZLL34.SGD","LU1093756168.USD","LU0203347892.USD","LU0795875086.SGD","SG9999015978.USD","LU1791710400.SGD","LU2361045086.USD","LU1066051811.HKD","LU1732799900.SGD","LU0198837287.USD","BK4539","LU1868837136.USD","LU2111349929.HKD","LU1244550494.USD","LU0251131958.USD","LU0820561818.USD","IE00B1BXHZ80.USD","LU2468319806.SGD","LU2023250843.SGD","LU0321505439.SGD","LU0314106906.USD","LU0868494617.USD","LU1880398554.USD","CURB","LU0795875169.SGD","LU0820561909.HKD","MRK","BK4512","LU1894683264.USD","OKLS","BK4231","LU0971096721.USD","LU1988902786.USD","LU1791710582.SGD","LU1201861165.SGD","OKLL","LU2361044949.HKD","LU0310800965.SGD","LU0557290698.USD","ARES","LU2324357040.USD","LU0048573561.USD","LU1057294990.SGD","IE000M9KFDE8.USD","LU1934455194.USD","LU0158827781.USD","LU0070302665.USD","IE00BJJMRZ35.SGD","BK4187","LU2491050071.SGD","LU1116320737.USD","LU0006306889.USD","LU0417517546.SGD","LU0061475181.USD","BK4553","LU1989771016.USD","BK4135","LU1363072403.SGD","LU1989772923.USD","LU0943347566.SGD","BK4550","LU1894683348.USD","LU2125909593.SGD","LU1699723380.USD","LU0158827948.USD","BK4566","LU0170899867.USD","LU0320765646.SGD","LU2491050154.USD","LU0648001328.SGD","SG9999014559.SGD","LU2360032135.SGD","LU0859254822.USD","LU1244550577.SGD","IE00BGHQF748.EUR","IE000MB6IJN5.SGD","LU0310799852.SGD","SG9999002232.USD","SG9999015358.SGD","BK4127","LU0289739699.SGD","SG9999014542.SGD","BK4603","LU2089984988.USD","SG9999015986.USD","LU1496350171.SGD","LU2106854487.HKD","SG9999014567.USD","LU1934455863.HKD","IE0004445239.USD","LU1668664300.SGD","SG9999015945.SGD","LU1037948897.HKD","LU2023251221.USD","LU2487616109.SGD","LU0738911758.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558365","title":"Unicycive Therapeutics Shares Down 36.9% Premarket After US FDA Declines to Approve Co's Kidney Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558365","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558365?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:22","pubTimestamp":1782818521,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nFWN4320FJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647558398","title":"Unicycive Therapeutics receives complete response letter from FDA for OLD NDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2647558398","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647558398?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:20","pubTimestamp":1782818437,"startTime":"0","endTime":"0","summary":"Unicycive Therapeutics (UNCY) announced that it has received a complete response letter, or CRL, from the FDA regarding the resubmitted new drug ap...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-receives-complete-response-letter-from-fda-for-old-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/unicycive-therapeutics-receives-complete-response-letter-from-fda-for-old-nda-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4539","OLD","BK4139","BK4585","LABU","BK4588","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647353028","title":"US FDA Declines to Approve Unicycive's Drug for Dialysis Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2647353028","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647353028?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:09","pubTimestamp":1782817784,"startTime":"0","endTime":"0","summary":"US FDA declines to approve Unicycive's drug for dialysis patientsJune 30 (Reuters)-The U.S. Food and Drug Administration declined to approve Uniycive Therapeutics'UNCY.Odrug to treat elevated phosphate levels in chronic kidney disease patients on dialysis, the company said on Tuesday.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nL4N42H0O9:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","UNCY","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530413","title":"Unicycive Says FDA Issues CRL for OLC NDA over Third-party Manufacturing Deficiencies","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530413","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530413?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:05","pubTimestamp":1782817523,"startTime":"0","endTime":"0","summary":"Unicycive says FDA issues CRL for OLC NDA over third-party manufacturing deficienciesUnicycive received an FDA complete response letter for its resubmitted NDA for oxylanthanum carbonate for hyperphos","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nNDL3wf7z5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","NDAQ","IE00BN0W2W23.USD","LU2095319765.USD","SG9999014005.SGD","IE00B64PRP62.GBP","BK4139","SG9999014013.SGD","UNCY","IE00BGHQF748.EUR","IE00BN0W2V16.EUR","BK4112","LU2210149790.SGD","SG9999014021.USD","IE00BKPKM429.USD","IE00B3QW5Z07.USD","BK4539","IE00BN0W2T93.GBP","BK4585","SG9999014039.USD","LU0314104364.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530437","title":"Unicycive Therapeutics - FDA Raises no Concerns on Clinical Efficacy or Safety Data, no Additional Data Requested","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530437","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530437?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:05","pubTimestamp":1782817500,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA17GLNB:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647530427","title":"Unicycive Therapeutics: Remain Confident in Efficacy & Safety of Olc; Optimistic That We Will be Able to Expeditiously Resubmit Nda","url":"https://stock-news.laohu8.com/highlight/detail?id=2647530427","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647530427?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:05","pubTimestamp":1782817500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA17GLNB:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647453045","title":"Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (olc) New Drug Application (nda)","url":"https://stock-news.laohu8.com/highlight/detail?id=2647453045","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647453045?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:05","pubTimestamp":1782817500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA17GLNB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","BK4539","UNCY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647434530","title":"Unicycive Therapeutics - FDA Has not Conducted Inspection of Third-party Manufacturing Vendor for Resubmitted Nda","url":"https://stock-news.laohu8.com/highlight/detail?id=2647434530","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647434530?lang=en_us&edition=fundamental","pubTime":"2026-06-30 19:05","pubTimestamp":1782817500,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260630:nTUA17GLNB:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4539","UNCY","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.unicycive.com","stockEarnings":[{"period":"1week","weight":0.09},{"period":"1month","weight":-0.1693},{"period":"3month","weight":-0.262},{"period":"6month","weight":-0.202},{"period":"1year","weight":0.2644},{"period":"ytd","weight":-0.0139}],"compareEarnings":[{"period":"1week","weight":-0.0047},{"period":"1month","weight":0.0021},{"period":"3month","weight":0.0521},{"period":"6month","weight":0.0861},{"period":"1year","weight":0.1901},{"period":"ytd","weight":0.0973}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Unicycive Therapeutics, Inc., a biotechnology company, develops treatments for various medical conditions in the United States. Its drug candidates include UNI 494, a pro-drug of Nicorandil that is being developed as a treatment for acute kidney injury; and Renazorb (Oxylanthanum Carbonate), which is being developed for the treatment of hyperphosphatemia in patients with chronic kidney disease. Unicycive Therapeutics, Inc. has license agreements with Shilpa Medicare Ltd; Sphaera Pharma Pte. Ltd.; Syneos Health LLC; Inotiv; Lee's Pharmaceutical (HK) Limited; Celerion; and Lotus International Pte Ltd. The company was incorporated in 2016 and is based in Los Altos, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":-0.078139},{"month":2,"riseRate":0.6,"avgChangeRate":0.088088},{"month":3,"riseRate":0.4,"avgChangeRate":0.59683},{"month":4,"riseRate":0.4,"avgChangeRate":-0.11937},{"month":5,"riseRate":0.4,"avgChangeRate":-0.060546},{"month":6,"riseRate":0,"avgChangeRate":-0.217882},{"month":7,"riseRate":0.2,"avgChangeRate":-0.039804},{"month":8,"riseRate":0.2,"avgChangeRate":-0.122604},{"month":9,"riseRate":0.6,"avgChangeRate":0.038818},{"month":10,"riseRate":0.8,"avgChangeRate":0.050976},{"month":11,"riseRate":0.6,"avgChangeRate":0.060673},{"month":12,"riseRate":0.4,"avgChangeRate":0.09852}],"exchange":"NASDAQ","name":"Unicycive Therapeutics, Inc.","nameEN":"Unicycive Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Unicycive Therapeutics, Inc.,UNCY,Unicycive Therapeutics, Inc.股票,Unicycive Therapeutics, Inc.股票老虎,Unicycive Therapeutics, Inc.股票老虎国际,Unicycive Therapeutics, Inc.行情,Unicycive Therapeutics, Inc.股票行情,Unicycive Therapeutics, Inc.股价,Unicycive Therapeutics, Inc.股市,Unicycive Therapeutics, Inc.股票价格,Unicycive Therapeutics, Inc.股票交易,Unicycive Therapeutics, Inc.股票购买,Unicycive Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Unicycive Therapeutics, Inc.(UNCY),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Unicycive Therapeutics, Inc.(UNCY) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}